Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News CASI Pharmaceuticals Inc CASI

Healthcare Biotechnology

CASI Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is focused on acquiring, developing, and commercializing products that augment its hematology oncology therapeutic focus as well as other areas of unmet medical need. Its... see more

Add To Watchlist

Recent & Breaking News (NDAQ:CASI)

CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma

PR Newswire March 30, 2015

CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results

PR Newswire March 27, 2015

CASI Pharmaceuticals Announces Initiation Of A Phase 2 Trial With ENMD-2076 In Triple-Negative Breast Cancer In China

PR Newswire March 25, 2015

CASI Pharmaceuticals Appoints Rong Chen, MD, Ph.D. As Chief Medical Officer

PR Newswire March 4, 2015

CASI Pharmaceuticals To Present At The 27th Annual ROTH Conference

PR Newswire March 3, 2015

CASI Pharmaceuticals Announces Receipt Of Final Minutes From FDA Meeting Regarding Clinical And Regulatory Path Of ENMD-2076 For The Treatment Of Patients With Fibrolamellar Carcinoma (FLC)

PR Newswire February 9, 2015

CASI Pharmaceuticals To Present At The 17th Annual BIO CEO & Investor Conference

PR Newswire February 2, 2015

CASI Pharmaceuticals Highlights 2014 Accomplishments And 2015 Milestones

PR Newswire January 16, 2015

CASI Pharmaceuticals To Hold Business Update Conference Call And Webcast On January 6th

PR Newswire December 23, 2014

CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma

PR Newswire December 17, 2014

CASI Pharmaceuticals Reports Third Quarter 2014 Financial Results

PR Newswire November 14, 2014

CASI Pharmaceuticals Announces Appointment Of Rajesh C. Shrotriya, MD To The Board Of Directors

PR Newswire September 23, 2014

Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs

Business Wire September 18, 2014

Spectrum Pharmaceuticals Out-Licenses Rights for Greater China to CASI Pharmaceuticals for Three of Its Drugs

PR Newswire September 18, 2014

CASI Pharmaceuticals Reports Second Quarter 2014 Financial Results

PR Newswire August 14, 2014

CASI Pharmaceuticals Receives Approval From CFDA To Conduct Phase II Clinical Trial With ENMD-2076 For Triple-Negative Breast Cancer In China

PR Newswire July 21, 2014

CASI Pharmaceuticals Receives U.S. Orphan Drug Designation For The Use Of ENMD-2076 To Treat Hepatocellular Carcinoma

PR Newswire July 7, 2014

EntreMed Stockholders Approve Name Change To CASI Pharmaceuticals

PR Newswire June 13, 2014

EntreMed appoints Franklin C. Salisbury, Jr., President of NFCR, to Board of Directors

PR Newswire June 3, 2014

EntreMed Announces Poster Presentations At ASCO On ENMD-2076

PR Newswire May 19, 2014